# US 8,748,370 B2 · Peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,748,370 B2
- Document ID: US8748370B2
- Status: Granted
- Kind: B2
- Application number: 13/379,146
- Filed: 2010-06-17
- Published: 2012-05-03
- Granted: 2014-06-10
- Earliest claimed: 2009-06-18
- Assignees: Strongbone AB
- Applicants: Anders Grubb; Franciszek Kasprzykowski; Ulf Lerner; Beata Zolnowska; Regina Kasprzykowska
- Inventors: Anders Grubb; Franciszek Kasprzykowski; Ulf Lerner; Beata Zolnowska; Regina Kasprzykowska
- Web page: https://patentgrep.com/patent/US8748370B2

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07K 5/06: Dipeptides
- C07K 5/06043: {Leu-amino acid}
- C07K 5/06052: {Val-amino acid}
- C07K 5/06095: {Arg-amino acid}
- C07K 5/08: Tripeptides
- C07K 5/10: Tetrapeptides
- C07K 5/1016: {and aromatic or cycloaliphatic}
- C07K 5/1019: {with the first amino acid being basic}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Novel compounds which may be for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation, bone resorption, or loosening of a prosthetic device.

## Claims

### Claim 1

A compound of the general formula (I)
R1-A-NH—CH(R2)—CO—R3 (I)
wherein,
R1 is Ar—X—, where X is (CH2)m—O—CO; (CH2)m—SO2—CH═CH—CO; CH═CH—CO; CO-oxirane-CO; CO—CH═CH—CO; CH2—CH═CH—CO; or (CH2)m—CO;
R1 is NH2—C(NH)—NH—(CH2)m—CO; or
R1 is an acyl residue containing hydroxylated coumarin moiety;
A is a bond or is one or more of Val or Leu;
R2 is isopropyl or isobutyl;
R3 is NH—(CH2)m—NH—C(NH)—NH2;
R3 is Phe-NH2; or
R3 is NH—CH(R4)—(CH2)m—NH-D, where R4 is C1-C6-alkyl, and D is CO—CH═CH—Ar, CO—CH═CH—SO2—(CH2)m—Ar, or Cum-Phe-, where Cum is an acyl residue containing hydroxylated coumarin moiety;
Ar is aryl or heteroaryl; and
m is an integer of 0 to 5;
the compound as a single stereoisomer or a mixture of different stereoisomers, or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, selected from the group consisting of:
A25
Sequence: Bzsa-Val-Leu-Agm
FW=550.7
A-26
Sequence: Cin-Val-Leu-Agm
FW=472.6
A-30
Sequence: Bac-Leu-Val-Agm
where Bac=3-benzylacroyl and Agm=agmatine (decarboxyarginine) residue
A-33
Sequence: Bzac-Val-Leu-Agm
FW=500.6
A-47
Sequence: (2S,3S)Bga-Val-Leu-Agm
FW=516.6
A-50
Sequence: (2R,3R)Bga-Val-Leu-Agm
FW=516.6
A54
A107
A-116
Sequence: Cin-DLeu-Leu-NH—(CH2)2—NH—(C═NH)—NH2
A-118
Sequence: Cin-Leu-Leu-NH—(CH2)3—NH—(C═NH)—NH2
A-119
Sequence: Cin-DVal-Leu-Agm
A-120
Sequence: Cin-DLeu-Leu-Agm
A-123
Sequence: Cin-DLeu-Leu-NH—(CH2)5—NH—(C═NH)—NH2
A-127
Sequence: 3 Pac-DLeu-Leu-Agm
and
A-128
Sequence: Cum-DLeu-LeuNH—(CH2)4NH—(C═NH)—NH2
FW=558.7
the compound as a single stereoisomer or a mixture of different stereoisomers, or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The compound according to claim 2, selected from the group consisting of: A-25, A-26, A-30, A-33, A-47, A-50, and A-54, as a single stereoisomer or a mixture of different stereoisomers, or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 2)

The compound according to claim 2, selected from group consisting of: A-107, A-116, A-118, A-119, A-120, A-123, A-127 and A-128 as a single stereoisomer or a mixture of different stereoisomers, or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

A pharmaceutical composition, comprising the compound according to claim 1 and a pharmaceutically acceptable carrier, buffer, excipient or diluent.

### Claim 6 (depends on 1)

A prosthetic device, comprising the compound according to claim 1.

### Claim 7 (depends on 5)

A prosthetic device, comprising the pharmaceutical composition according to claim 5.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein R4 is isopropyl.

### Claim 9 (depends on 1)

The compound according to claim 1, wherein Ar is phenyl or pyridyl.

### Claim 10 (depends on 2)

The compound according to claim 2, selected from group consisting of: A-33, A-47 and A-107, as a single stereoisomer or a mixture of different stereoisomers, or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 2)

The compound according to claim 2, wherein the compound is A-107.

### Claim 12 (depends on 1)

A method of inhibiting osteoclast formation or activity in a subject in need thereof, comprising administering to the subject an effective amount of the compound according to claim 1.
